Stage IVA Lip and Oral Cavity Cancer AJCC v8 Clinical Trials

13 clinical trials for Stage IVA Lip and Oral Cavity Cancer AJCC v8 across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer — RECRUITING · PHASE2
• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer — RECRUITING · PHASE2
• Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial — RECRUITING · PHASE2
• Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer — RECRUITING · PHASE1
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery — RECRUITING · PHASE2
• Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer — RECRUITING · PHASE2
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin — COMPLETED · PHASE2
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin — ACTIVE_NOT_RECRUITING · PHASE1
• Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin — NOT_YET_RECRUITING · PHASE3
• A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery — TERMINATED · PHASE1
• Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin — COMPLETED · PHASE2

Refine this search